23 August 2021 : Clinical Research
Cost-Benefit Analysis of Using A Single Dose of Tranexamic Acid in Degenerative Lumbar Scoliosis Patients Undergoing Long-Segment Spinal Fusion Surgery: A Retrospective Study
Lei Yuan123BCE, Yu Jiang123BD, Yinhao Liu123BF, Yan Zeng123ADF*, Zhongqiang Chen123A, Weishi Li123BDOI: 10.12659/MSM.930352
Med Sci Monit 2021; 27:e930352
Table 3 Data from subanalyses of patients without osteotomy.
| NTXA (n= 59) | TXA (n=13) | P value | |
|---|---|---|---|
| Sex, F/M (n) | 44/15 | 11/2 | 0.681 |
| Age (years) | 63.88±6.31 | 65.08±6.41 | 0.539 |
| BMI (Kg/m) | 25.87±4.29 | 26.02±3.63 | 0.905 |
| Hypertension (n, %) | 23 (39.0%) | 5 (38.5%) | 0.972 |
| Diabetes mellitus (n, %) | 11 (18.6%) | 4 (30.8%) | 0.550 |
| EBV (mL) | 4687.03±876.04 | 4666.15±593.39 | 0.935 |
| ASA physical status, I: II: III (n) | 10:46:3 | 2:10:1 | 0.934 |
| Cobb angle (°) | 25.13±8.03 | 24.45±4.52 | 0.679 |
| CSVL (mm) | 20.71±10.21 | 25.43±13.54 | 0.160 |
| SVA (mm) | 56.62±42.37 | 48.17±37.51 | 0.509 |
| LL angle (°) | 31.67±15.46 | 31.78±19.70 | 0.983 |
| Pre-operative Hb (g/L) | 136.83±13.80 | 133.85±11.58 | 0.473 |
| Pre-operative hematocrit (%) | 41.09±3.8 | 41.00±3.1 | 0.939 |
| Pre-operative PLT (×10/L) | 223.89±63.59 | 236.15±53.11 | 0.246 |
| Pre-operative APTT (S) | 32.34±2.50 | 31.78±2.68 | 0.478 |
| Pre-operative INR | 1.00±0.06 | 0.99±0.07 | 0.675 |
| Post-operative D1 Hb (g/L) | 104.50±15.60 | 105.08±15.71 | 0.905 |
| Post-operative D1 hematocrit (%) | 31.18±4.5 | 31.92±4.5 | 0.590 |
| Hb change (g/L) | 31.98±15.03 | 28.77±12.56 | 0.479 |
| Hematocrit change (%) | 10.00±4.4 | 9±3.5 | 0.546 |
| ASD-S score | 20.75±3.81 | 20.31±3.09 | 0.700 |
| Duration of surgery (min) | 239.32±49.44 | 220.00±39.30 | 0.192 |
| Fixation and fused levels (n) | 4.93±0.98 | 4.77±0.83 | 0.580 |
| Decompression levels (n) | 3.27±1.08 | 3.08±0.86 | 0.546 |
| No. of intervertebral fusion (n) | 1.35±0.78 | 1.46±0.66 | 0.620 |
| IBL (mL) | 1125.15±641.40 | 719.15±444.45 | * |
| Postoperative drainage (mL) | 1385.54±465.34 | 1035.23±404.14 | * |
| Total blood loss (mL) | 2510.69±867.31 | 1754.38±727.72 | ** |
| Cell saver (mL) | 375.05±213.80 | 239.72±148.15 | 0.034* |
| Intraoperative PRBC | 1.97±1.95 | 1.69±1.60 | 0.638 |
| Intraoperative transfusion rate (n, %) | 36 (61.0%) | 8 (61.5%) | 0.972 |
| Postoperative PRBC | 2.12±2.59 | 1.08±1.55 | 0.168 |
| Postoperative transfusion rate (n, %) | 34 (57.6%) | 5 (38.5%) | 0.209 |
| 11.00±4.71 | 9.31±2.93 | 0.219 | |
| 0 | 0 | – | |
| Values are presented as the mean±SD or number (%). TXA – the group that received tranexamic acid; NTXA – the historically recruited no-TXA group; BMI – body mass index; EBV – estimated blood volume; ASA – American Society of Anesthesiologists; CSVL – coronal vertical axis from the central sacrum vertical line; SVA – sagittal vertical axis; LL – lumbar lordosis; Hb – hemoglobin; PLT – platelets; APTT – activated partial thromboplastin time; INR – international normalized ratio; ASD-S – adult spinal deformity surgery; IBL – intraoperative blood loss; PRBC – packed red blood cells; DVT – deep vein thrombosis; PE – pulmonary embolism. * ** | |||